Holen Sie sich die Stockscreener-App
1.94
8.38%
0.15
Handel nachbörslich:
1.91
-0.03
-1.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.79
Offen:
$1.83
24-Stunden-Volumen:
9.26M
Relative Volume:
1.91
Marktkapitalisierung:
$384.51M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.9151
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+1.04%
1M Leistung:
+63.03%
6M Leistung:
+3.74%
1J Leistung:
+7.78%
1-Tages-Spanne:
$1.82
$2.03
1-Wochen-Bereich:
$1.70
$2.03
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.94 | 358.36M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - MSN
Published on: 2025-08-10 18:32:11 - beatles.ru
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Will Esperion Therapeutics Stock Surge Sustain? - StocksToTrade
Esperion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Market Access, Growth Strategies, and Revenue Projections - AInvest
Transcript : Esperion Therapeutics, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Esperion Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ESPR) - Seeking Alpha
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises - Investing.com Canada
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises By Investing.com - Investing.com South Africa
Esperion Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Esperion Therapeutics Q2 Earnings: Narrower Loss and Revenue BeatNews and Statistics - IndexBox
Esperion Reports 12% Revenue Growth in Q2 2025 with Significant Increases in U.S. Product Sales and Settlements with ANDA Filers - Quiver Quantitative
Esperion Therapeutics Q2 revenue up 12%, operating profit beats estimates - MarketScreener
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Esperion Reports Record 42% Revenue Growth, Secures Patent Protection Until 2040 in Breakthrough Quarter - Stock Titan
How many analysts rate Esperion Therapeutics Inc. as a “Buy”Discover top stock picks for aggressive growth - Jammu Links News
Is Esperion Therapeutics Inc. a good long term investmentAchieve rapid financial growth with expert help - Jammu Links News
What are the latest earnings results for Esperion Therapeutics Inc.Free Market Dynamics Reports - Jammu Links News
What are the technical indicators suggesting about Esperion Therapeutics Inc.Strong return on investment - Jammu Links News
Should I hold or sell Esperion Therapeutics Inc. stock in 2025Rapid wealth multiplication - Jammu Links News
Is Esperion Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
Is Esperion Therapeutics Inc. a growth stock or a value stockFree Stock Chart Pattern Guide - Jammu Links News
What institutional investors are buying Esperion Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What is the dividend policy of Esperion Therapeutics Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
Esperion Therapeutics Inc. Stock Analysis and ForecastCapitalize on stocks with high profit margins - Jammu Links News
How strong is Esperion Therapeutics Inc. company’s balance sheetUnlock powerful portfolio management tools - Jammu Links News
What are Esperion Therapeutics Inc. company’s key revenue driversExceptional trading performance - Jammu Links News
How does Esperion Therapeutics Inc. compare to its industry peersFree Stock Outlook That Work - Jammu Links News
Esperion Therapeutics soars amid vague takeover speculation - MSN
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):